Efficacy and Patient-Reported Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Aumolertinib as First-Line Therapy: A Real-World Study

In this real-world study involving 33 advanced non-small cell lung cancer (NSCLC) patients, aumolertinib demonstrated a disease control rate of 91.3% and an objective response rate of 65.2%, aligning with results from the AENEAS trial. Over a median follow-up of 264 days, patient-reported outcomes (PROs) improved significantly, with reductions in symptoms such as cough, sore mouth or tongue, tingling in hands or feet, and various pain sites after 6 months of treatment. These findings suggest that aumolertinib not only effectively controls disease progression but also enhances quality of life, supporting its use as a first-line therapy for NSCLC patients with EGFR-sensitizing mutations.